Monte Rosa Therapeutics(GLUE) - 2025 Q2 - Quarterly Results

Phase 1/2 study of GSPT1-directed MGD MRT-2359 advancing in heavily pretreated, castration-resistant prostate cancer patients; additional results on track for H2 2025 Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic appr ...